二、董事会会议审议情况 证券代码：300534 证券简称：陇神戎发 公告编号：2025-076 甘肃陇神戎发药业股份有限公司 第五届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第二十 四次会议于 2025 年 11 月 4 日在公司六楼会议室现场召开，本次会议以豁免通知 时限形式于 2025 年 11 月 4 日以书面形式通知全体董事。本次会议由公司董事长 康永红先生主持，应出席会议董事 9 人，实际出席会议董事 9 人，公司高级管理 人员列席了会议。本次会议的召集、召开符合《公司法》等有关法律、行政法规、 部门规章和《公司章程》的相关规定，合法有效。 会议审议并通过了如下议案： 1.审议通过《关于调整公司第五届董事会专门委员会委员的议案》 鉴于公司独立董事人员发生变动，为完善公司治理结构，董事会同意补选独 立董事方文彬先生接替已离任独立董事李宗义先生担任第五届董事会审计委员 会主任委员及薪酬与考核委员会委员职务，任期与第五届董事会一致，董事会 ...

Core Viewpoint - The stock of Longshen Rongfa has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.17% but a slight decline in the last five days, indicating mixed market sentiment towards the company [1][2]. Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million yuan, representing a year-on-year decrease of 19.71%. However, the net profit attributable to shareholders increased by 9.13% to 27.03 million yuan [2]. - Cumulatively, the company has distributed 42.64 million yuan in dividends since its A-share listing, with 24.27 million yuan distributed over the past three years [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Longshen Rongfa increased to 27,800, up by 2.21% from the previous period. The average number of circulating shares per shareholder decreased by 2.16% to 10,866 shares [2]. - Among the top ten circulating shareholders, the Huatai-PB Zhongzheng Traditional Chinese Medicine ETF holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3]. Market Activity - On October 31, the stock price of Longshen Rongfa rose by 2.03% to 10.06 yuan per share, with a trading volume of 33.21 million yuan and a turnover rate of 1.10%. The total market capitalization stands at 3.052 billion yuan [1]. - The net inflow of main funds was 1.6073 million yuan, with large orders accounting for 15.07% of total purchases [1]. Business Overview - Longshen Rongfa, established on June 3, 2002, and listed on September 13, 2016, is primarily engaged in the production and sales of traditional Chinese medicine. The revenue breakdown includes 86.53% from pharmaceutical sales, 6.69% from medical devices, and smaller contributions from logistics, rental, and consulting services [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [1].

甘肃陇神戎发药业股份有限公司 关于控股子公司收到药品注册上市许可申请 《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，甘肃陇神戎发药业股份有限公司控股子公司甘肃普安制药股份有限公 司（以下简称"普安制药"）收到国家药品监督管理局下发的布瑞哌唑口溶膜境 内药品注册上市许可申请的《受理通知书》，现将相关情况公告如下： 一、《受理通知书》主要信息 （一）申请单位：甘肃普安制药股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：布瑞哌唑口溶膜 规格：2mg 证券代码：300534 证券简称：陇神戎发 公告编号：2025-074 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 （二）申请单位：甘肃普安制药股份有限公司 申请事项：境内生产药品注册上市许可 产品名称：布瑞哌唑口溶膜 规格：1mg 受理号：CXHS2500132 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决 定予以受理。 产品名称：布瑞哌唑口溶膜 受理号：CXHS2500131 （三）申请单位：甘肃普安制药股份有限公司 申请事项： ...

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. reported steady growth in revenue and net profit for the first three quarters of 2025, driven by the recovery of the traditional Chinese medicine industry and the enhancement of its core product competitiveness [1][2]. Financial Performance - The company achieved an operating income of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1]. - The net profit excluding non-recurring gains and losses was 28.71 million yuan, up 31.14% year-on-year [1]. Market Position and Product Development - Longshen Rongfa has focused on optimizing its market sales layout, consolidating the market share of its core products, and exploring the market potential of existing generic drugs [2]. - The company’s two exclusive products, Yuanhu Zhitong Pill and Xuanfei Zhike Mixture, have seen increased market competitiveness and brand influence, ranking in the top 20 for various categories in public medical institutions [2]. Production Capacity and R&D - A new production line for the Xuanfei Zhike Mixture has been established, capable of producing 50 million boxes annually, ensuring a solid supply for the market [3]. - The company emphasizes product R&D as a core driver of sustainable development, with ongoing projects for product development and clinical trials [3]. Future Outlook - The company plans to continue focusing on traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [3].

Group 1 - The core point of the article is that Longshen Rongfa reported a decline in revenue for the first three quarters of 2025, while net profit attributable to shareholders increased [1] Group 2 - For the first three quarters of 2025, the company achieved operating income of 647,287,705.63 yuan, representing a year-on-year decrease of 16.12% [1] - The net profit attributable to shareholders was 27,029,405.74 yuan, showing a year-on-year growth of 8.11% [1]

Core Viewpoint - The company reported steady growth in its operating performance for the first three quarters of 2025, driven by the recovery of the traditional Chinese medicine industry and the enhancement of its core product competitiveness [1] Financial Performance - The company achieved operating revenue of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1] - The net profit after deducting non-recurring gains and losses was 28.71 million yuan, showing a year-on-year growth of 31.14% [1] Product Development and Market Position - The company focuses on the development of traditional Chinese medicine, with core products such as Yuanhu Zhitong Pill and Xuanfei Zhike Decoction gaining market share and brand influence [2] - Yuanhu Zhitong Pill ranked 15th in the "Top 20 Sales of Traditional Chinese Medicine Pills in Public Medical Institutions" for the first half of 2024, while Xuanfei Zhike Decoction ranked 6th in the "Top 20 Cough and Phlegm Relief Traditional Chinese Medicines" [2] - The company is advancing the secondary development of its main products, including real-world studies for Xuanfei Zhike Decoction and Yuanhu Zhitong Pill, and is progressing with the construction of a production line for blood dialysis concentrate [3] Strategic Focus - The company will continue to concentrate on its core business of traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [4]

Core Viewpoint - Longshen Rongfa (300534) demonstrated robust operational performance and growth momentum in the first three quarters of 2025, achieving a revenue of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1] Group 1: Financial Performance - The company reported a net profit of 27.03 million yuan, with a year-on-year growth of 8.11%, while the net profit after deducting non-recurring gains and losses reached 28.71 million yuan, marking a significant increase of 31.14% [1] - The overall recovery of the traditional Chinese medicine industry has positively impacted the company's performance, supported by the strengthening competitiveness of its core products and continuous deepening of its industrial layout [1] Group 2: Product Performance - The company's two exclusive products, Yuanhu Zhitong Droplets and Xuanfei Zhiso Mixture, have been key drivers of growth, with Yuanhu Zhitong Droplets ranking 15th in the "Top 20 Brands of Traditional Chinese Medicine Pills in Public Medical Institutions" for H1 2024 and 9th in the "Top 20 Gastrointestinal Products" for Q1 2025 [2] - Xuanfei Zhiso Mixture has solidified its position in the cough relief product segment, ranking 6th in the "Top 20 Brands of Cough and Phlegm Relief Traditional Chinese Medicine" for 2024 and 7th in the "Top 20 Innovative Drug Sales Enterprises (Traditional Chinese Medicine)" at the 90th National Pharmaceutical Trade Fair in 2025 [2] Group 3: Research and Development - The company views innovation as a core driver of sustainable development, continuing to advance secondary development of its main products, including real-world studies for Xuanfei Zhiso Mixture and Yuanhu Zhitong Droplets [3] - The subsidiary, Puan Pharmaceutical, has received clinical trial approval for the modified new drug Bupropion Oral Film and is progressing with the construction and registration of a production line for blood dialysis concentrate [3] - The company is also expanding its health product portfolio, with new offerings such as plant-based beverages and herbal extracts gaining consumer attention and positive feedback [3] Group 4: Future Outlook - Looking ahead to the fourth quarter, the company plans to maintain its focus on traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [3]

陇神戎发(300534.SZ)发布2025年三季度报告，该公司前三季度营业收入为6.47亿元，同比减少16.12%。 归属于上市公司股东的净利润为2702.94万元，同比增长8.11%。归属于上市公司股东的扣除非经常性损 益的净利润为2871.34万元，同比增长31.14%。基本每股收益为0.0891元。 ...

Group 1 - Company LongShen RongFa reported Q3 performance with revenue of approximately 647 million yuan, a year-on-year decrease of 16.12% [1] - The net profit attributable to shareholders was approximately 27.03 million yuan, an increase of 8.11% year-on-year [1] - Basic earnings per share were 0.0891 yuan, reflecting an increase of 8.13% year-on-year [1] Group 2 - The market capitalization of LongShen RongFa is currently 3.1 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion USD this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market faces challenges in fundraising [2]

Core Viewpoint - The company reported a significant decline in revenue for the third quarter, indicating potential challenges in its operational performance [1] Financial Performance - The third quarter revenue was 151 million yuan, a year-on-year decrease of 34.63% [1] - The net profit for the third quarter was a loss of 926,700 yuan [1] - For the first three quarters, the total revenue was 647 million yuan, reflecting a year-on-year decline of 16.12% [1] - The net profit for the first three quarters was 27.03 million yuan, which represents a year-on-year increase of 8.11% [1]